EP1071436A4 - Immune effector cell hybrids - Google Patents

Immune effector cell hybrids

Info

Publication number
EP1071436A4
EP1071436A4 EP99903347A EP99903347A EP1071436A4 EP 1071436 A4 EP1071436 A4 EP 1071436A4 EP 99903347 A EP99903347 A EP 99903347A EP 99903347 A EP99903347 A EP 99903347A EP 1071436 A4 EP1071436 A4 EP 1071436A4
Authority
EP
European Patent Office
Prior art keywords
immune effector
effector cell
cell hybrids
hybrids
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99903347A
Other languages
German (de)
French (fr)
Other versions
EP1071436A1 (en
Inventor
Bruce L Roberts
Charles A Nicolette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of EP1071436A1 publication Critical patent/EP1071436A1/en
Publication of EP1071436A4 publication Critical patent/EP1071436A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/46447—Mucins, e.g. MUC-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99903347A 1998-01-26 1999-01-25 Immune effector cell hybrids Withdrawn EP1071436A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8835798P 1998-01-26 1998-01-26
US88357P 1998-01-26
US8004198P 1998-03-31 1998-03-31
US80041P 1998-03-31
PCT/US1999/001464 WO1999037313A1 (en) 1998-01-26 1999-01-25 Immune effector cell hybrids

Publications (2)

Publication Number Publication Date
EP1071436A1 EP1071436A1 (en) 2001-01-31
EP1071436A4 true EP1071436A4 (en) 2003-08-27

Family

ID=26762993

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99903347A Withdrawn EP1071436A4 (en) 1998-01-26 1999-01-25 Immune effector cell hybrids

Country Status (5)

Country Link
EP (1) EP1071436A4 (en)
JP (2) JP2002500872A (en)
AU (1) AU2339299A (en)
CA (1) CA2318987A1 (en)
WO (1) WO1999037313A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
EP1168924A4 (en) * 1999-03-31 2002-09-04 Univ Pittsburgh In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
HUP0402656A3 (en) * 2001-02-20 2012-03-28 Ortho Mcneil Pharm Inc A cell therapy method for the treatment of tumors
FR2828934B1 (en) * 2001-08-27 2004-08-13 Inst Nat Sante Rech Med TEST OF CELL IMMUNITY BY FIXED PEPTIDES ON SOLID SUPPORT
EP1558723A4 (en) * 2002-11-07 2006-02-15 Johnson & Johnson Res Pty Ltd A means of producing and utilising a population of disease specific cytotoxic t-lymphoctyes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
WO1998046785A1 (en) * 1997-04-15 1998-10-22 Dana-Farber Cancer Institute, Inc. Dendritic cell hybrids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
WO1998046785A1 (en) * 1997-04-15 1998-10-22 Dana-Farber Cancer Institute, Inc. Dendritic cell hybrids

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ALBERT M L ET AL: "IMMATURE DENDRITIC CELLS PHAGOCYTOSE APOPTOTIC CELLS VIA ALPHA V BETA 5 AND CD36, AND CROSS-PRESENT ANTIGENS TO CYTOTOXIC T LYMPHOCYTES", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 188, no. 7, 5 October 1998 (1998-10-05), pages 1359 - 1368, XP000906793, ISSN: 0022-1007 *
ALBERT MATTHEW L ET AL: "Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 392, no. 6671, 5 March 1998 (1998-03-05), pages 86 - 89, XP002154749, ISSN: 0028-0836 *
CELLUZZI C M ET AL: "Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 160, no. 7, 1 April 1998 (1998-04-01), pages 3081 - 3085, XP002167051, ISSN: 0022-1767 *
DUNNION D ET AL: "Human antigen presenting cell/tumour cell hybrids as candidate cancer vaccines", EUROPEAN JOURNAL OF IMMUNOGENETICS 1998 UNITED KINGDOM, vol. 25, no. 1, 1998, pages 58, XP009007824, ISSN: 0960-7420 *
GONG J ET AL: "INDUCTION OF ANTIGEN-SPECIFIC ANTITUMOR IMMUNITY WITH ADENOVIRUS- TRANSDUCED DENDRITIC CELLS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 4, no. 10, October 1997 (1997-10-01), pages 1023 - 1028, XP002910552, ISSN: 0969-7128 *
GONG J L ET AL: "FUSION OF HUMAN BREAST TUMOR AND DENDRITIC CELLS AS A NOVEL ANTITUMOR VACCINE", PROCEEDINGS OF THE 89TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. NEW ORLEANS, LA, MARCH 28 - APRIL 1, 1998, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA: AACR, US, vol. 39, March 1998 (1998-03-01), pages 172, XP002910557 *
GUO YAJUN ET AL: "Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 263, no. 5146, 28 January 1994 (1994-01-28), pages 518 - 520, XP002167016, ISSN: 0036-8075 *
JIANLIN GONG ET AL: "INDUCTION OF ANTITUMOR ACTIVITY BY IMMUNIZATION WITH FUSIONS OF DENDRITIC AND CARCINOMA CELLS", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 3, no. 5, May 1997 (1997-05-01), pages 558 - 561, XP002919846, ISSN: 1078-8956 *
LESPAGNARD L ET AL: "DENDRITIC CELLS FUSED WITH MASTOCYTOMA CELLS ELICIT THERAPEUTIC ANTITUMOR IMMUNITY", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 76, 1998, pages 250 - 258, XP002951123, ISSN: 0020-7136 *
See also references of WO9937313A1 *
WANG J ET AL: "Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines", JOURNAL OF IMMUNOLOGY 15 NOV 1998 UNITED STATES, vol. 161, no. 10, 15 November 1998 (1998-11-15), pages 5516 - 5524, XP002234896, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
CA2318987A1 (en) 1999-07-29
WO1999037313A1 (en) 1999-07-29
EP1071436A1 (en) 2001-01-31
JP2002500872A (en) 2002-01-15
JP2009195235A (en) 2009-09-03
AU2339299A (en) 1999-08-09

Similar Documents

Publication Publication Date Title
GB9819260D0 (en) Solar cell arrangements
EP0971430A4 (en) Battery
HK1025186A1 (en) Battery
GB9904905D0 (en) Cells
EP1071436A4 (en) Immune effector cell hybrids
KR20010012684A (en) Solar battery
EP0969542A4 (en) Battery
IL124830A0 (en) Solar collector
HK1027469A1 (en) Hybrid module
AU4434499A (en) Cif130 inhibits cell cycle progression
GB9805817D0 (en) Battery
GB9919227D0 (en) Solar cell
EP1037969A4 (en) Fibrinogen-converting enzyme hybrids
ZA981734B (en) Photovoltaic cell
GB9826883D0 (en) Improved photovoltaic cell
AU1455P (en) Sunabell Brachyscome hybrid
IL126800A0 (en) Hybrid power plant
AU138982S (en) Solar still
GB9809826D0 (en) Solar still
PL325177A1 (en) Solar cell
GB2337167B (en) Power lines
GB9806905D0 (en) Charger
TW417909U (en) Charger
TW379892U (en) Charger
AU1876P (en) Southern Sunrise Hebe hybrid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000726

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20030715

17Q First examination report despatched

Effective date: 20030829

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

Owner name: GENZYME CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101218